Publication details
Alirocumab v léčbě hypercholesterolemie
| Title in English | Alirocumab in tne treatment of hypercholesterolemia |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Popularization text |
| MU Faculty or unit | |
| Citation | |
| Description | Proprotein convertase subtilisin/kexin type 9 (PCSK-9) plays an important role in lipoprotein metabolism, mainly by reducing number of LDL receptors on the surface of hepatocytes. Alirocumab is a fully human igG1 monoclonal antibody with high affinity to circulating PCSK-9. Alirocumab increases number of LDL receptors on hepatocytes and thus lowers LDL-cholesterol levels. The efficacy of alirocumab has been evaluated in more than 23 500 patients with primary hypercholesterolemia. In phase lil trials, alirocumab was shown to reduce LDL-cholesterol levels up to 62 % compared to placebo and up to 36 % compared to ezetimibe. In these trials, alirocumab had an acceptable safety profile and it was well tolerated. After its launch in the Czech Republic, alirocumab will be ušed in high cardiovascular risk patients with hypercholesterolemia which is not being sufficiently controlled by maximally tolerated doses of lipid lowering drugs. The ongoing ODYSSEY OUTCOMES trial is supposed to provide evidence on the effect of alirocumab on cardiovascular morbidity and mortality and missing data on its long-term safety and tolerability. |